Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism

Molecular Cell

Volumn 12, Issue 4, 2003, Pages 805-816

  Castrillo, Antonio ^a   Joseph, Sean B ^a   Vaidya, Sagar A ^a   Haberland, Margaret ^a   Fogelman, Alan M ^a   Cheng, Genhong ^a   Tontonoz, Peter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; INTERFERON REGULATORY FACTOR 3; LIGAND; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ABCA 1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BACTERIUM; CELL CULTURE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ESCHERICHIA COLI; GENE; GENE INDUCTION; GENE TARGETING; GENETIC TRANSCRIPTION; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROMOTER REGION; SALMONELLA TYPHIMURIUM; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; VIRUS;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0242361567     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(03)00384-8     Document Type: Article

References (60)

1. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 9:1998;143-150.
2. Alber D.G., Powell K.L., Vallance P., Goodwin D.A., Grahame-Clarke C. Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation. 102:2000;779-785.
3. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 413:2001;732-738.
4. Barton G.M., Medzhitov R. Toll-like receptors and their ligands. Curr. Top. Microbiol. Immunol. 270:2002;81-92.
5. Barton G.M., Medzhitov R. Linking Toll-like receptors to IFN-alpha/beta expression. Nat. Immunol. 4:2003;432-433.
6. Boekholdt S.M., Agema W.R., Peters R.J., Zwinderman A.H., van der Wall E.E., Reitsma P.H., Kastelein J.J., Jukema J.W. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 107:2003;2416-2421.
7. Brown M.S., Goldstein J.L. Lipoprotein metabolism in the macrophage. implications for cholesterol deposition in atherosclerosis Annu. Rev. Biochem. 52:1983;223-261.
8. Buja L.M. Does atherosclerosis have an infectious etiology? Circulation. 94:1996;872-873.
9. Byrne G.I., Kalayoglu M.V. Chlamydia pneumoniae and atherosclerosis. links to the disease process Am. Heart J. 138:1999;S488-S490.
10. Castrillo A., Diaz-Guerra M.J., Hortelano S., Martin-Sanz P., Bosca L. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12, 14)-prostaglandin J(2) in activated murine macrophages. Mol. Cell. Biol. 20:2000;1692-1698.
11. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K.et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7:2001;161-171.
12. Chiu B., Viira E., Tucker W., Fong I.W. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation. 96:1997;2144-2148.
13. Costet P., Luo Y., Wang N., Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275:2000;28240-28245.
14. Doyle S., Vaidya S., O'Connell R., Dadgostar H., Dempsey P., Wu T., Rao G., Sun R., Haberland M., Modlin R.et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 17:2002;251-263.
15. Doyle S.E., O'Connell R., Vaidya S.A., Chow E.K., Yee K., Cheng G. Toll-like receptor 3 mediates a more potent antiviral response than toll-like receptor 4. J. Immunol. 170:2003;3565-3571.
16. Dubuquoy L., Jansson E.A., Deeb S., Rakotobe S., Karoui M., Colombel J.F., Auwerx J., Pettersson S., Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology. 124:2003;1265-1276.
17. Edfeldt K., Swedenborg J., Hansson G.K., Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions. a possible pathway for plaque activation Circulation. 105:2002;1158-1161.
18. Epstein S.E. The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ. Res. 90:2002;2-4.
19. Fitzgerald M.L., Mendez A.J., Moore K.J., Andersson L.P., Panjeton H.A., Freeman M.W. ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space. J. Biol. Chem. 276:2001;15137-15145.
20. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., Coyle A.J., Liao S.M., Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4:2003;491-496.
21. Glass C.K., Witztum J.L. Atherosclerosis. the road ahead. Cell. 104:2001;503-516.
22. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91:2002;281-291.
23. Hwang S.Y., Hertzog P.J., Holland K.A., Sumarsono S.H., Tymms M.J., Hamilton J.A., Whitty G., Bertoncello I., Kola I. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl. Acad. Sci. USA. 92:1995;11284-11288.
24. Janeway C.A. Jr., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20:2002;197-216.
25. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 383:1996;728-731.
26. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N.et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA. 99:2002;7604-7609.
27. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9:2003;213-219.
28. Joyce C.W., Amar M.J., Lambert G., Vaisman B.L., Paigen B., Najib-Fruchart J., Hoyt R.F. Jr., Neufeld E.D., Remaley A.T., Fredrickson D.S. et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Natl. Acad. Sci. USA. 99:2002;407-412.
29. Kalayoglu M.V., Byrne G.I. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect. Immun. 66:1998;5067-5072.
30. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., Willeit J., Schwartz D.A. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347:2002;185-192.
31. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., McKee D.D., Oliver B.B., Willson T.M., Zetterstrom R.H.et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 92:1998;73-82.
32. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A. Jr., Medzhitov R., Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 110:2002;191-202.
33. Krutzik S.R., Ochoa M.T., Sieling P.A., Uematsu S., Ng Y.W., Legaspi A., Liu P.T., Cole S.T., Godowski P.J., Maeda Y.et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat. Med. 9:2003;525-532.
34. Laffitte B.A., Joseph S.B., Walczak R., Pei L., Wilpitz D.C., Collins J.L., Tontonoz P. Autoregulation of the human liver X receptor alpha promoter. Mol. Cell. Biol. 21:2001;7558-7568. a.
35. Laffitte B.A., Repa J.J., Joseph S.B., Wilpitz D.C., Kast H.R., Mangelsdorf D.J., Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. USA. 98:2001;507-512. b.
36. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A.et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272:1997;3137-3140.
37. Libby P. Inflammation in atherosclerosis. Nature. 420:2002;868-874.
38. Lusis A.J. Atherosclerosis. Nature. 407:2000;233-241.
39. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1:2001;135-145.
40. Medzhitov R., Janeway C.A. Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 296:2002;298-300.
41. Moazed T.C., Campbell L.A., Rosenfeld M.E., Grayston J.T., Kuo C.C. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J. Infect. Dis. 180:1999;238-241.
42. Naghavi M., Barlas Z., Siadaty S., Naguib S., Madjid M., Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 102:2000;3039-3045.
43. Ophuls Arteriosclerosis and cardiovascular disease. their relation to infectious diseases JAMA. 76:1921;700-702.
44. Oram J.F. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr. Opin. Lipidol. 13:2002;373-381.
45. Patel P., Mendall M.A., Carrington D., Strachan D.P., Leatham E., Molineaux N., Levy J., Blakeston C., Seymour C.A., Camm A.J.et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 311:1995;711-714.
46. Rassu M., Cazzavillan S., Scagnelli M., Peron A., Bevilacqua P.A., Facco M., Bertoloni G., Lauro F.M., Zambello R., Bonoldi E. Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions. Atherosclerosis. 158:2001;73-79.
47. Repa J.J., Mangelsdorf D.J. The liver X receptor gene team. potential new players in atherosclerosis Nat. Med. 8:2002;1243-1248.
48. Sato M., Suemori H., Hata N., Asagiri M., Ogasawara K., Nakao K., Nakaya T., Katsuki M., Noguchi S., Tanaka N., Taniguchi T. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity. 13:2000;539-548.
49. Sharma S., tenOever B.R., Grandvaux N., Zhou G.P., Lin R., Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science. 300:2003;1148-1151.
50. Tangirala R.K., Bischoff E.D., Joseph S.B., Wagner B.L., Walczak R., Laffitte B.A., Daige C.L., Thomas D., Heyman R.A., Mangelsdorf D.J.et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA. 99:2002;11896-11901.
51. Tontonoz P., Mangelsdorf D.J. Liver x receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17:2003;985-993.
52. Toshchakov V., Jones B.W., Perera P.Y., Thomas K., Cody M.J., Zhang S., Williams B.R., Major J., Hamilton T.A., Fenton M.J.et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat. Immunol. 3:2002;392-398.
53. van Eck M., Bos I.S., Kaminski W.E., Orso E., Rothe G., Twisk J., Bottcher A., Van Amersfoort E.S., Christiansen-Weber T.A., Fung-Leung W.P.et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl. Acad. Sci. USA. 99:2002;6298-6303.
54. Van Lenten B.J., Wagner A.C., Nayak D.P., Hama S., Navab M., Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 103:2001;2283-2288.
55. Van Lenten B.J., Wagner A.C., Anantharamaiah G.M., Garber D.W., Fishbein M.C., Adhikary L., Nayak D.P., Hama S., Navab M., Fogelman A.M. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 106:2002;1127-1132.
56. Venkateswaran A., Laffitte B.A., Joseph S.B., Mak P.A., Wilpitz D.C., Edwards P.A., Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA. 97:2000;12097-12102.
57. Vink A., Schoneveld A.H., van der Meer J.J., van Middelaar B.J., Sluijter J.P., Smeets M.B., Quax P.H., Lim S.K., Borst C., Pasterkamp G.et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation. 106:2002;1985-1990.
58. Weaver B.K., Kumar K.P., Reich N.C. Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1. Mol. Cell. Biol. 18:1998;1359-1368.
59. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., Glass C.K. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. USA. 100:2003;6712-6717.
60. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., Luthringer D., Xu X.P., Rajavashisth T.B., Yano J.et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 104:2001;3103-3108.